SEATTLE--(BUSINESS WIRE)--Nov. 6, 2017--
Omeros Corporation (NASDAQ: OMER), today announced that the company will
issue its third quarter 2017 financial results for the period ended
September 30, 2017, on Thursday, November 9, 2017, after the market
closes. Omeros management will host a conference call and webcast that
day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the
financial results.
Conference Call Details
To access the live conference call
via phone, please dial (844) 831-4029 from the United States and Canada
or (920) 663-6278 internationally. The participant passcode is 8389089.
Please dial in approximately 10 minutes prior to the start of the call.
A telephone replay will be available for one week following the call and
may be accessed by dialing (855) 859-2056 from the United States and
Canada or (404) 537-3406 internationally. The replay passcode is 8389089.
To access the live and subsequently archived webcast of the conference
call, go to Omeros’ website at www.omeros.com
and go to “Events” under the Investors section of the website. Please
connect to the website at least 15 minutes prior to the call to allow
for any software download that may be necessary.
About Omeros Corporation
Omeros is a commercial-stage
biopharmaceutical company committed to discovering, developing and
commercializing small-molecule and protein therapeutics for large-market
as well as orphan indications targeting inflammation,
complement-mediated diseases and disorders of the central nervous
system. The company’s drug product OMIDRIA® (phenylephrine
and ketorolac injection) 1% / 0.3% is marketed for use during cataract
surgery or intraocular lens (IOL) replacement to maintain pupil size by
preventing intraoperative miosis (pupil constriction) and to reduce
postoperative ocular pain. In the European Union, the European
Commission has approved OMIDRIA for use in cataract surgery and other
IOL replacement procedures to maintain mydriasis (pupil dilation),
prevent miosis (pupil constriction), and to reduce postoperative eye
pain. Omeros has multiple Phase 3 and Phase 2 clinical-stage development
programs focused on: complement-associated thrombotic microangiopathies;
complement-mediated glomerulonephropathies; Huntington’s disease and
cognitive impairment; and addictive and compulsive disorders. In
addition, Omeros has a diverse group of preclinical programs and a
proprietary G protein-coupled receptor (GPCR) platform through which it
controls 54 new GPCR drug targets and corresponding compounds, a number
of which are in preclinical development. The company also exclusively
possesses a novel antibody-generating platform.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171106005570/en/
Source: Omeros Corporation
Cook Williams Communications, Inc.
Jennifer Cook Williams
Investor
and Media Relations
360.668.3701
